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Abstract
One of the greatest challenges in the treatment of substance dependence is to reverse the control that drug-associated
stimuli have gained over the addict’s behavior, as these drug-associated memories increase the risk of relapse even after
long periods of abstinence. We report here that inhibition of the atypical protein kinase C isoform PKCzeta and its
constitutively active isoform PKMzeta with the pseudosubstrate inhibitor ZIP administered locally into the nucleus
accumbens core reversibly inhibited the retrieval of drug-associated memory and drug (remifentanil) seeking, whereas a
scrambled ZIP peptide or staurosporine, an effective inhibitor of c/nPKC-, CaMKII-, and PKA kinases that does not affect
PKCzeta/PKMzeta activity, was without effect on these memory processes. Acquisition or extinction of drug-associated
memory remained unaffected by PKCzeta- and PKMzeta inhibition.
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Introduction
Drug dependence has remained a formidable therapeutic
challenge because, among others, the underlying maladaptive
behavior is remarkably resistant to change, even when such a
change is the focus of psychotherapeutic interventions [1]. Recent
animal experimental findings, however, indicate that drug-
associated memories may be amenable to genetic/pharmacologic
manipulation during the memory reconsolidation phase [2,3]:
Cocaine-conditioned place preference could be inhibited by
bilateral local administration into the nucleus accumbens core
(AcbC) of inhibitors of mitogen-activated protein kinases (MEKs)
[4] or antisense oligonucleotides of the immediate early gene
zif268 (egr1) [5], while acquisition of a new operant response could
be blocked by zif268 knockdown in the basolateral amygdala
(BLA) [5,6,7] but not the AcbC (see Discussion).
We could recently demonstrate that activation of both
muscarinic and nicotinic acetylcholine receptors located in the
AcbC is necessary for the acquisition of rat runway behavior
conditioning by drugs of abuse [8] but not food [9] (but see
[10,11], confirming previous findings obtained in a lever-press-
based self-administration paradigm [12]. Muscarinic acetylcholine
receptors (mAChRs) are known to activate conventional, novel,
and atypical isotypes of the protein kinase C (PKC) family [13].
Activation of atypical PKCs (aPKCs) was found to be required for
the firing of Acb medium spiny neurons [14], the activation of
which is necessary for operant behavior under a second order
schedule of responding [15]. We therefore investigated the
expression, phosphorylation and activity of PKC isoforms, in
particular PKMzeta, in the AcbC during the consolidation,
storage, retrieval, and reconsolidation of associative memories
involved in drug seeking. To that end, we employed the rat
runway paradigm, because of its considerable face validity for the
human situation and because it is well suited to quantify the
control that drug-associated contextual stimuli exert over an
individual’s behavior [16], moved to Discussion: although the most
differentiating behavioral analysts [17] emphasize that the rat
runway paradigm, like the conditioned place preference (CPP)
procedure and other maze paradigms, is not able to distinguish
between Pavlovian (i.e., respondent) approach (insensitive to
changes in action-outcome contingencies and thus not truly
goal-directed) and operant behavior (sensitive to changes in action-
outcome contingencies). We shall therefore use the term
‘‘(conditioned) approach to drug’’ to describe the rats’ behaviour
because this term reflects the minimum theoretical consensus that
can be obtained.
As a prototypical drug of abuse, we chose to test remifentanil
instead of cocaine (arguably the most popular experimental drug
of abuse), because the mu opioid agonist remifentanil has a much
less complex signal transduction pathway than cocaine while
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distribution into the brain, fast elimination from deep brain
structures, and fast esteratic degradation in the blood [18,19]. In
addition, self-administration of remifentanil is proportional over a
much larger unit dose range than cocaine, most likely because self-
administration of remifentanil is much less limited by the
compound’s concurrent aversive properties than that of cocaine
[16].
Materials and Methods
Subjects and animal care
Male Sprague Dawley rats were obtained from the Research
Institute of Laboratory Animal Breeding (Himberg, Austria)
weighing 250–300 g on receipt. Before surgery, all animals were
housed in groups of six at a constant room temperature of 24uC
and had free access to tap water and food. All rats were tested
during the light phase of a 12-hr light-dark cycle (lights on at
0700 h). The animals used in this study were cared for in
accordance with the guidelines of the National Institutes of Health
Animal Care and Use Program and the NIDA-IRP Animal
Program, which is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International. Furthermore, the present experiments were ap-
proved by the national Animal Experiment Ethics Committee.
Morphine was obtained from the Innsbruck University Hospital
Pharmacy, all other chemicals were obtained from Sigma-Aldrich
(Vienna, Austria) unless indicated otherwise. Doses and concen-
trations refer to pure base.
Implantation of intravenous catheters and intra-
accumbens infusion cannulae
Male Sprague Dawley rats were implanted under isoflurane (2–
4%; Abbott, Vienna) anesthesia with guide cannulae 48 h before
the actual experiments and previously with self-made jugular vein
catheters [8] with the following dimensions: 0.6 mm inner
diameter (ID)61.2 mm outer diameter (OD)60.3 mm silicone
tubing thickness. On test day, infusion cannulae were advanced to
tip coordinates of AP+1.6 mm relative to bregma, ML - 1.6 mm,
and DV 8.2 mm [20]. Only experiments in which the cannula tip
location was confirmed by visual inspection of post-mortem brain
slices to be within the AcbC limits as defined in the Paxinos and
Watson atlas were included in the study.
Runway behavior
In the operant runway procedure [21,22][9,23], the time that
an animal needs to obtain a stimulus, the ‘‘runtime’’, is commonly
thought to be inversely proportional to the apparent [16]
reinforcing strength of that stimulus Using the runway procedure,
we could reliably demonstrate acquisition of drug seeking for
opioids and psychostimulants within only five consecutive trials in
completely drug- and experiment-naive rats [8,9,18,22]. In the
present study, two days after the implantation of the intravenous
(i.v.) catheters and the guide cannulae, completely drug- and
experiment-naı ¨ve rats were given the opportunity to run for access
to an i.v. injection of 0.032 mg/kg remifentanil (www.glaxosmith-
kline.com) for four consecutive trials (‘‘runs’’; intertrial interval,
40 min). This remifentanil dose was chosen because it was the
highest dose that proved to be a reliable positive reinforcer in
previously published runway experiments from our group (see
Figure 3 of [22]) and was shown to to result in a robust in vivo
microdialysis neurotransmitter release signal [8]. The inter-trial
interval of 40 min was chosen to allow elimination of .90% of the
drug from the AcbC between runs (see Figure 1 of [8] to avoid
direct pharmacological effects of remifentanil (e.g., sedation). Runs
were started by opening a sliding door separating a start area from
the main alley (length, 1 m) of the runway and by indicating
availability of i.v. remifentanil with a white cue light in the goal
area. The click of a photobeam and the blinking of the cue light
indicated the successful completion of the response for the run-
Table 1. Details of the behavioral experimental design and timeline.
Experiment 1 acquisition admin test
run 1–4 (309)5
RMF (n=13) rmf veh x
RMF+ZIP (n=5) rmf ZIP x
Saline (n=9) sal veh x
Experiment 2 acquisition (day 1) test (day 2) reminder (day 3) reacq. (day 4) test
run 1 2 3 4 1–3 1–2 1–5 6
RMF+ZIP (n=7) QZIP rmf rmf QZIP x rmf rmf x
RMF+ZIP scr (n=8) QZIPs rmf rmf QZIPs x rmf rmf x
RMF+Stauro (n=7) QStau rmf rmf QStau x rmf rmf x
Experiment 3
acquisition (day 1) ZIP admin (day 2) retrieval reinst. (day 4) reacq. (day 5)
run 1–14 (309) 1–8 1–7 1–5
RMF+ZIP (n=9) rmf Q x rmf (1) rmf
RMF+ZIP scr (n=10) rmf Q x rmf (1) rmf
RMF+ZIP control (n=7) rmf Q rmf (1) rmf
rmf: remifentanil, veh: vehicle, sal: saline, admin: administration, reacq: reaquisition, reinst: reinstatement, stau: staurosporine, zips: zip scramble, x: trials without drug
reinforcement, Q: intraaccumbens injection, rmf(1): self-administration of remifentanil only after completion of the first run.
doi:10.1371/journal.pone.0030502.t001
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e30502Figure 1. Local intra-AcbC inhibition of PKC/Mzeta the retrieval of conditioned remifentanil approach-associated memories. (A)
Runway behavior before ZIP administration, runs #1-4: Drug-naı ¨ve male Sprague Dawley rats were given the opportunity to traverse a runway alley
to obtain 0.032 mg/kg i.v. RMF (contingent RMF administration, i.e., RMF self-administration, 40 min inter-run interval; RMF, N=13) or saline (SAL,
N=9) paired with a light stimulus (conditioned stimulus, CS; blinking at 2 Hz for 20 s)[8] (B) Runway behavior after ZIP administration, run #5: In
order to determine the goal time in absence of the drug with its confounding sedative effects, RMF was not administered in this last run. The
PKCzeta- und PKMzeta-pseudosubstrate inhibitor ZIP (0.5microliter of 1.5 mM) was administered locally into the nucleus accumbens core (30 min
before run #5) of five animals after the first four RMF runs (RMF+ZIP). Column 1 shows start time (i.e., latency to leave the start area), column 2 alley
time (i.e., time needed to traverse the runway alley), and column 3 goal time (i.e., time spent in the goal area). In order to determine the effect of
noncontingent RMF (i.e., the acute pharmacological effects of RMF) on PKCzeta- and PKMzeta activation (see Fig. 3), another group of animals
passively received i.v. RMF within the confines of the runway (noncontingent RMF administration, N=10). Their runway behavior was not recorded
and is therefore not shown here. The statistical analysis gave the following results: Panel A1, 2W-RM-ANOVA, Interaction [F(6,19)]=7,875 P,0.0001.
Group [F(2,19)]=16,44 P,0.0001, post-hoc (Bonferroni): ZIP vs Saline (run3: p,0.05, run4: p,0.001), RMF vs Saline(run3: p,0.001, run4:p,0.001).
Panel B1: 1W-ANOVA F(2,19)=52.90 p,0.0001, post-hoc (Bonferroni): RMF+ZIP vs Saline (p,0.001), RMF+ZIP vs RMF (ns), RMF vs Saline (p,0.001)).
Panel B3, 1W-ANOVA F(2,19)=13,66 p,0,0002, post-hoc (Bonferroni): RMF+ZIP vs Saline (ns), RMF+ZIP vs RMF (p,0.05), RMF vs Saline (p,0.001)).
doi:10.1371/journal.pone.0030502.g001
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tapes by a treatment-blinded experimenter [22] had shown that
when a positive reinforcer is made available in the goal area, the
rats immediately leave the start area, i.e., commit to approaching
the reinforcer-associated goal area immediately, and approach the
goal area without engaging in alternative behavior. In contrast,
both an increase in the latency to leave the start area and an
increase in alternative behavior in the runway alley had been
consistently observed with saline as compared to i.v. drugs of
abuse. Consequently, three behavioral components were recorded,
ie (1) the start area time, defined as the time elapsed between the
placement of the animal within the start area and the exit of the
whole animal from the area once the sliding door had been
opened by the researcher; (2) the alley time as the time elapsed
between the animal’s exit of the start area and the entry of the
whole animal into the goal area, and (3) the goal time as the
duration of the animal’s stay in the goal area with the sole
administration of a CS+ (up to 15 seconds) until it retreated back
leaving the area completely. For the animals that received an US+
(i.e., remifentanil) just after a complete entry, such a time was not
measured due to the direct effects of the drug on locomotion.
Runway dimensions and experimental details have been published
previously [22,24,25]. Details of the experimental design and
timeline could be found in Table 1.
Brain tissue lysate preparation and subcellular
fractionation
Rats were sacrificed at the end of the experiment, their brains
were immediately recovered, generously washed in ice-cold saline,
and were dissected immediately on ice. The tissue was immedi-
ately homogenized with a mechanical tissue disrupter in hypotonic
lysis buffer (20 mM Tris-HCl, pH 7.5, 2 mM MgCl2,1 0m M
KCl, 10 mM ß-glycerophosphate, 5 mM Na4P2O7610 H2O,
2 mM EDTA, 2 mM EGTA, protease inhibitor mix HP from
www.serva.de), was incubated on ice for 30 min and was
centrifuged at 2506 g to get rid of debris. The lysate was
subsequently centrifuged at 100,0006 g for 1 h, and the
supernatant was stored as ‘‘cytosolic fraction’’ at 270uC. The
pellet was resuspended in hypotonic lysis buffer+2% Triton X-100
with repeated vortexing for 1 hour on ice, and was stored as
‘‘membrane fraction’’ at 270uC.
Immunoblotting
Subcellular fractions as well as non-fractionated lysates
(homogenized in lysis buffer with 50 mM Tris, 50 mM NaCl,
5m M N a 4P2O7610 H2O, 5 mM EDTA, 2% Triton X-100,
adjusted to pH 7.3, plus protease inhibitor mix HP from Serva,
www.serva.de) were normalized to protein concentrations with a
detergent compatible protein assay (Bio-rad, www.biorad.com).
Ten microgram protein were boiled for 5 min with 56 SDS
sample buffer and subjected to SDS-PAGE gel electrophoresis
using a 4% stacking gel and 10% separating gel. Proteins in the gel
were electrophoretically transferred to nitrocellulose membranes,
followed by immunoblotting with an antibody to PKC zeta
(1:1500; Santa Cruz Biotechnology) diluted in TBST with 5%
milk. Bound antibody was visualized with horseradish peroxidase-
conjugated secondary antibody (1:2000, Santa Cruz Biotechnol-
ogy) and enhanced chemiluminescence. Antibodies to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH, 1:2500; www.abcam.
com) were used as loading controls and were incubated along with
the primary antibodies to PKC zeta.
Data analysis
Unless indicated otherwise, values are given as means 6 S.E.M.
of N determinations. If one-way- or two-way (dependent on the
experiment) repeated measures-corrected ANOVA yielded a
p,0.05, groups were compared with Bonferroni post-hoc test.
Statistical tests were performed with SPSSH (www.spss.com).
Results
Experiment 1 (Figs. 1 and 2) tested the effects of acute PKC/
Mzeta inhibition by ZIP which was administered locally into the
AcbC after runway behavior was acquired during the first 4
response-i.v. remifentanil-pairings. Thus, Experiment 1 most likely
assessed the effects of ZIP on the retrieval of memory regarding i.v.
remifentanil-associated contextual conditioned stimuli (CS) and of
the behavior previously associated with these contextual CSs.
Acute ZIP administration increased the latency to leave the start
area of the runway apparatus by about 25% (Fig. 1B1, assuming
the latency difference between remifentanil-conditioned behaviour
and saline-conditioned behavior to be 100%). ZIP also decreased
the time that the rat spent in the goal area after the i.v. injection of
remifentanil by about 30% (Fig. 1B3). Of note, running speed
through the 1-m alley that connected the start area with the goal
area was not affected by any treatment (i.e., contingent i.v. saline
vs remifentanil or contingent remifentanil in absence or presence
of acute intra-AcbC ZIP).
The acquisition and expression of conditioned remifentanil
approach in the runway (Fig. 1) was paralleled by an activation of
PKCzeta and PKMzeta in the AcbC, as evidenced (Fig. 2) by a
shift in the membrane/cytosol ratio of both the 100 kDa and
75 kDa subunits of PKCzeta and PKMzeta (55 kDa). This effect
was dependent on the contingent administration of i.v. remifenta-
nil and could be fully inhibited by intra-AcbC ZIP. Noncontingent
remifentanil, i.e., i.v. remifentanil that the rat passively received
within the confines of the runway had no effect on PKCzeta and
PKMzeta activation.
Experiment 2 shows that PKCzeta and PKMzeta inhibition by
ZIP was able to block memory consolidation while having no
effect on memory acquisition. Although ZIP was administered
intra-AcbC twice during the memory acquisition phase, i.e., before
runs #1 and #4 of the first experimental day (Fig. 3A1), i.e., no
Figure 2. Acquisition and expression of conditioned remifentanil approach is paralleled by an activaction of PKC/Mzeta in the
AcbC. The animals, the behavior of which is shown in Fig. 1, were sacrificed immediately after run #5 (see Fig. 1B), brain tissue lysates were obtained
from the nucleus accumbens core (AcbC) and subcellular fractions were separated by ultracentrifugation. Ten micrograms of membrane- (m) or
cytosolic (c) fraction were separated by SDS-PAGE, transferred to nitrocellulose membranes, and incubated with antibody (1:1500) against PKCzeta
(top panel, 100 kDa subunit band; middle panel; 75 kDa subunit band). This antibody also detected PKMzeta (bottom panel; 55 kDa band). Bound
antibody was visualized with horseradish peroxidase-conjugated secondary antibody (1:2000, Santa Cruz Biotechnology) and enhanced
chemiluminescence. GAPDH immunoreactivity was used as a loading control. Activation of PKCzeta and PKMzeta is reflected by the membrane/
cytosol ratio (abscissae; means 6 SEM). S, saline (N=9), NC, noncontingent remifentanil (N=10), C, contingent remifentanil (N=8), C+ZIP, contingent
remifentanil followed by ZIP inhibition (N=5). ANOVAs and Bonferroni post-hoc tests for each subunit gave the following results: 100 kDa subunit,
F(3,28)=3.001; p,0.05,* p,0.05 for C vs NC; 75 kDa subunit, F(3,28)=3.698; p,0.023 * # p,0,05 for C vs NC and C vs S; and 55 kDa subunit,
F(3,28)=4,383; p,0.012; p,0.05 for C vs C+ZIP.
doi:10.1371/journal.pone.0030502.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30502Figure 3. Inhibition of AcbC PKC/Mzeta blocks memory consolidation. Rats were trained to traverse a runway alley to obtain a remifentanil
(RMF; 0.032 mg/kg iv) injection paired with a light stimulus (conditioned stimulus, CS; blinking at 2 Hz for 20 s) on day A (acquisiton; top row). The
PKCzeta- and PKMzeta-pseudosubstrate inhibitor ZIP (N=7), scrambled ZIP peptide (N=8), or the nonselective PKC inhibitor staurosporine (N=7)
was administered locally into the nucleus accumbens core (0.5microliter of 1.5 mM each) 30 min before runs #1 and #4. On day B, only the light
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pattern most plausibly resulted in appreciable intra-AcbC ZIP
levels at the end of the experiment, too, thus affecting memory
consolidation as well. Fig. 3B1 shows that on the next day, i.e.,
upon retesting the rats in the runway, ZIP which had been
administered during the end of the previous day’s experiment
considerably increased start area latency before run #1, clearly
indicating that ZIP had inhibited consolidation of the remifenta-
nil-associated memory the day before. In contrast, scrambled ZIP
or staurosporine, an effective inhibitor of c/nPKC-, CaMKII-,
and PKA kinases that does not affect PKCzeta/PKMzeta activity
[26], had no effect. ZIP also inhibited the increase in goal time
engendered by i.v. remifentanil (Fig. 3B3). Again, scrambled ZIP
or staurosporine failed to affect goal time. If a drug reminder cue
was administered the next day (Fig. 3C), conditioned remifentanil
approach was fully re-established, indicating that the drug cue
was able to override any additional effect on memory reconso-
lidation ZIP may have exerted on the previous day. The
inhibition of memory consolidation by ZIP was fully reversible,
as the retraining session performed two days later shows (Fig. 3D).
As in Experiment 1, alley running speed was not affected by any
of the treatments.
The effects of PKCzeta and PKMzeta inhibition on memory
reconsolidation were tested in Experiment 3 (Fig. 4): After
conditioned remifentanil approach had been acquired (Fig. 4A),
animals were exposed to ZIP during a session (Fig. 4B) in which
conditioned remifentanil approach was elicited by the light CS
alone, plausibly leading to relevant ZIP levels during the
reconsolidation phase after that session (Fig. 4B). If the rats were
tested with the remifentanil reminder cue one day later (Fig. 4C),
start latency (Fig. 4C1) was increased and goal time (Fig. 4C3)
was decreased, strongly suggesting that the reconsolidation of
these two components of the overall conditioned remifentanil
approach behavior was inhibited. In contrast, if ZIP was
administered noncontingently in the rats’ home cages (ZIPcon-
trol) without the animals being exposed to the light CS, these
behaviors were not changed. Interestingly, although scrambled
ZIP did not affect behavior on the first run of that day (Figs. 4C1
and 4C3) – indicating that it did not affect reconsolidation, the
treatment with scrambled ZIP speeded up extinction during the
remifentanil reminder cue session as compared to the group that
did receive ZIP in their home cage without undergoing the light
CS reminder cue session. This plausibly indicates that the light
CS reminder cue session constituted an extinction trial the effect
of which, however, was first overridden by the drug reminder cue
(run #1) but the extinction effect of which managed to emerge
during the (unreinforced) subsequent runs of this session (Fig. 4C).
As in all previous experiments, alley running speed was not
affected by any of the treatments. All effects were reversible as the
rats’ behavior in the subsequent retraining session (Fig. 4D)
shows.
Discussion
Our findings indicate that local intra-AcbC activation of
PKCzeta and PKMzeta but not PKC is necessary for the retrieval,
consolidation and reconsolidation of drug-associated memories
necessary for conditioned drug approach as determined in a rat
runway paradigm [8,9], confirming previous findings obtained in a
lever-press-based self-administration paradigm [12]. The results of
the present study strongly suggest PKCzeta and PKMzeta as a
downstream target of the AcbC acetylcholine signal necessary for
the acquisition of drug approach and, thus, conditioning of drug-
associated contextual stimuli, an effect that seems to be
preferential for drug- vs food reinforcers [9], but see [10,11].
Using a very broad methodological approach including optoge-
netic inhibition, Deisseroth and co-workers [27] very plausibly
identified cholinergic interneurons in the AcbC as the originator of
the microdialysis signal observed by us previously [8,9]. Optoge-
netic inhibition of these AcbC ACh interneurons prevented
acquisition of cocaine CPP [27]. By generous extrapolation, one
may assume that not only CPP behavior but ‘‘drug craving’’ may
also be mediated by these AcbC ACh interneurons. As these AcbC
ACh interneurons (1) comprise less than 1% of the Acb neuron
population [28]and as (2) these AcbC ACh interneurons represent
the AcbC’s only known cholinergic input [29], they offer an ideal
target for a therapeutic intervention.
The present findings contribute to the following anatomical
differentiation regarding the different aspects of drug seeking
(please see the discussion in [5]: While activation of the AcbC [4,5]
[4,5](present study), and ACh interneuron activation in the AcbC
(i.e., in the brain region medial of the anterior commissure) in
particular [27], is necessary for establishing and maintaining drug-
associated (contextual?) memories relevant for ‘‘maze’’ [17]
behavior which is most likely strongly dependent on contextual
cues (i.e., CPP- or runway behavior), operant conditioning, i.e.,
acquisition of a new operant response, depends on the activation
of the BLA [5,6,7] but not the AcbC [5]. Accordingly, in our
hands, local intra-AcbC PKCzeta and PKMzeta inhibition
affected the latency to commit to traversing the runway and the
time spent in the i.v. remifentanil injection-associated goal area
(arguably a measure similar to the ‘‘time spent in the drug-
associated compartment’’ as observed in the CPP paradigm), while
not affecting the actual running speed (possibly the most ‘‘operant’’
component of the runway behavior).
Our findings also indicate that while a drug reminder (drug
priming, see data of run #1 in figs. 4C1 and 4C3) overrides
previous CS-based extinction training (Fig. 4B), subsequent
extinction of drug primining-induced drug approach is facilitated
by previous CS-based extinction training. Extrapolating to the
human situation, our data indicate that while a drug-induced lapse
may override previous therapeutic endeavors, these therapeutic
interventions may still shorten the duration of drug-associated
stimulus (CS) was presented when the animal had traversed the runway (all groups). One day later (day C), all animals received i.v. RMF upon
traversing the alley in run #1. Traversing the runway in run #2 had no consequences. The next day (day D), all animals were retrained with RMF plus
the light CS. No RMF was administered in run #5 in order to determine goal times. Column 1, start time; column 2; alley time; column 3, goal time
(not determined on day A because of direct sedative effects of RMF). The statistical analysis yielded the following results: Panel B1: 2W-RM-ANOVA:
Interaction: F(6,19)=1,0327; run number: F(3,19)=40,51 p,0,0001; Group F(2,19)=9,771; p,0,01, posthoc (Bonferroni): ZIP vs ZIP-scrambled: runs
1,3 p,0,05. ZIPscramble vs Staurosporine: NS. ZIP vs staurosporine, runs 2,3 p,0.05. Panel B3: 1W-ANOVA Only for 1
st run. F(2,19)=24.870; p,0.001.
Posthoc/Bonferroni: ZIP vs ZIP-scramble: p,0.001; ZIP vs Stauro: p,0.001; ZIP-scramble vs Stauro: NS. Panel C1: 1W-ANOVA Only for 2
nd run.
F(2,19)=9.341; p,0.001, posthoc (Bonferroni). ZIP vs ZIP-scramble d; p,0.01. ZIP vs STAURO, p,0.05. staurosporine vs ZIP-scrambled. NS. Panel C3:
1W-ANOVA: F(2,19)=6.995; p,0.01. Posthoc (Bonferroni) ZIP vs ZIP-scrambled p,0.01. ZIP–scrambled vs staurosporine, NS. ZIP vs staurosporine,
p,0.05. Panel D1: 2W-RM-ANOVA. Interaction: F(8,19)=3,106 p,0.01; Run Number F(4,19)=22,17 p,0.0001. Group: F(2,19)=22.51 p,0.0001.
Posthoc (Bonferroni): ZIP vs ZIP-scrambled: runs 1,2 (p,0.01) and 3 (p,0.05). ZIP-scrambled vs staurosporine. NS. ZIP vs staurosporine runs 1,2,3
p,0.01. Panel D3: 1-W-ANOVA: F(2,19)=1.044. NS.
doi:10.1371/journal.pone.0030502.g003
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30502Figure 4. Inhibition of AcbC PKC/Mzeta inhibits memory reconsolidation. Rats were trained to traverse a runway alley to obtain a
remifentanil (RMF; 0.032 mg/kg iv) injection paired with a conditioned light stimulus (conditioned stimulus, CS) on day A (top row). On day B (second
row), animals received either ZIP (0.5microliter of 1.5 mM; N=9) or scrambled ZIP peptide (N=10) within the confines of the runway (30 min prior to
starting run #1) and were presented only with the CS upon traversing the runway. The ZIPcontrol group (N=7) received ZIP in their home cage
without being tested in the runway. Two days later (C), the ZIP- and the scrambled peptide groups received an injection of RMF (drug-induced
reinstatement of responding) only after the first run of the day (arrow); ZIP-control animals did not receive the drug reminder; all rats were presented
with the CS upon entering the goal area. The next day (D), all animals were retrained with RMF+CS. Column 1, start time; column 2; alley time; column
3, goal time (not determined on days A and D because of confounding direct sedative effects of RMF). Column 1, start time; column 2; alley time;
column 3, goal time (determined in absence of RMF). Note that on days B and C, that for all animals that did not leave the start area, no alley times
and goal times could not be determined. Consequently, the number of animals that contributed to the mean times shown here were, on day B, run
#3, N=10 in the scrambled peptide group, and N=9 in the ZIP group; run #4, 10 scrambled, 9 ZIP; run #5, 10 scrambled, 6 ZIP; run #6, 10
scrambled, 8 ZIP; run #7, 7 scrambled, 8 ZIP; and run #8, 7 scrambled, 9 ZIP. On day C, the respective numbers were: run #3, 10 scrambled, 9 ZIP, 7
ZIP-control; run #4, 10 scrambled, 7 ZIP, 7 ZIP-control; run #5, 10 scrambled, 6 ZIP, 7 ZIP-control; run #6, 8 scrambled, 6 ZIP, 7 ZIP-control; run #7, 7
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are consequently applied. In other words, our findings suggest
that, in the human situation, even post-lapse therapy may still be
effective.
It has been argued that reconsolidation may be seen as
accelerated extinction (p.76 of [3]. We have no indication that
ZIP changed the speed of extinction (Figs. 3B1, Figs. 4B1).
Interestingly, acquisition of drug-conditioned place preference
(CPP) could be blocked by intracerebroventricular injection of
calphostin C (mouse morphine CPP [30]) or intra-Acb injection of
NPC15437 (rat amphetamine CPP [31]). Neither of these two
PKC inhibitors affects atypical PKCs [32]. It thus seems that
activation of PKCzeta/PKMzeta is not necessary for the
acquisition of drug-related memories whereas activation of other
kinases is.
Although many addiction researchers would agree [23] that the
rat runway paradigm constitutes a bona fide operant procedure
(with traversing the runway alley as the operant), the most
differentiating behavioral analysts [17] emphasize that the rat
runway paradigm, like the conditioned place preference (CPP)
procedure and other ‘‘maze’’ paradigms, is not able to distinguish
between Pavlovian (i.e., respondent) approach (insensitive to
changes in action-outcome contingencies and thus not truly
goal-directed) and operant behavior (sensitive to changes in action-
outcome contingencies). The rat runway paradigm, however, has
proven sensitive to changes in action-outcome contingencies, as
shown in the present study and in numerous previous ones
[8,9,21,22,23].
In conclusion, the present results contribute to the following
emerging picture: Drug-associated contextual stimuli acquire
control over an individual’s behavior through the activation of a
a very localized group of neurons, i.e., the AcbC cholinergic
interneurons [27], ‘‘accumbens core’’ designating a brain region
medial of and adjacent to the anterior commissure. This effect is
most likely mediated through the activation of M1 muscarinic
receptors [33] and the atypical protein kinase C isoforms PKCzeta
and PKMzeta in medium spiny neurons which are located
immediately medial of the anterior commissure (i.e., neurons of
the accumbal ‘‘core’’) and which project most abundantly to the
lateral ventral pallidum [34]. By extrapolation, these events may
be part of the phenomenon sometimes reported by humans as
‘‘drug craving’’ [35]. These findings, based on a number of
converging results obtained by several independent research
groups using very different experimental approaches, offer hope
for the targeted treatment of one of the most important
determinants of drug lapse and relapse [36].
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